Automated Lamellar Keratectomy in Symptomatic Patients With Bullous Keratopathy (ALKSBK)
Primary Purpose
Corneal Disease
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
ALK (automated lamellar keratectomy)
Mitomycin
Sponsored by
About this trial
This is an interventional treatment trial for Corneal Disease focused on measuring cataract extraction, surgery, corneal disease
Eligibility Criteria
Inclusion Criteria:
- Patient with bullous keratopathy symptomatic (with pain)
Exclusion Criteria:
- herpetic endotelial disorders
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Active Comparator
Arm Label
1
2
Arm Description
Group one submitted to automated lamellar keratectomy(ALK) with mitomycin (0,02% in 30 seconds after keratectomy).
automated lamellar keratectomy without mitomycin
Outcomes
Primary Outcome Measures
Pain questionnaire
Secondary Outcome Measures
biomicroscopy, esthesiometry, UBM pachymetry, impression cytology
Full Information
NCT ID
NCT00654888
First Posted
April 3, 2008
Last Updated
April 10, 2008
Sponsor
Federal University of São Paulo
1. Study Identification
Unique Protocol Identification Number
NCT00654888
Brief Title
Automated Lamellar Keratectomy in Symptomatic Patients With Bullous Keratopathy
Acronym
ALKSBK
Official Title
Study of Automated Lamellar Keratectomy With a New Option in Treatment in Symptomatic Patients With Bullous Keratopathy.
Study Type
Interventional
2. Study Status
Record Verification Date
April 2008
Overall Recruitment Status
Completed
Study Start Date
March 2005 (undefined)
Primary Completion Date
March 2006 (Actual)
Study Completion Date
February 2008 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Federal University of São Paulo
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
To relieve pain in patients with symptomatic bullous keratopathy (BK) until keratoplasty and in patients without visual prediction.
The automated lamellar keratectomy represents a alternative in treatment of pain in symptomatic patients with BK.
Detailed Description
Only patients with BK symptomatic (with pain) were submitted to automated lamellar keratectomy (ALK).
Complete ophthalmological examination including UCVA,BSVA, biomicroscopy, tonometry, esthesiometry, UBM pachymetry, impression cytology and pain questionnaire were performed in preoperative, postoperative of one, seven, 30, 90, 180 days and one year.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Corneal Disease
Keywords
cataract extraction, surgery, corneal disease
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Participant
Allocation
Randomized
Enrollment
28 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Active Comparator
Arm Description
Group one submitted to automated lamellar keratectomy(ALK) with mitomycin (0,02% in 30 seconds after keratectomy).
Arm Title
2
Arm Type
Active Comparator
Arm Description
automated lamellar keratectomy without mitomycin
Intervention Type
Procedure
Intervention Name(s)
ALK (automated lamellar keratectomy)
Other Intervention Name(s)
automated lamellar keratectomy with PTK
Intervention Description
ALK is performed with a microkeratome, to make a free cap.
Intervention Type
Drug
Intervention Name(s)
Mitomycin
Other Intervention Name(s)
automated lamellar keratectomy associated with PTK
Intervention Description
mitomycin 0,02%, 30 seconds after ALK
Primary Outcome Measure Information:
Title
Pain questionnaire
Time Frame
preoperative and postoperative 1,7,30,90,180 days and one year
Secondary Outcome Measure Information:
Title
biomicroscopy, esthesiometry, UBM pachymetry, impression cytology
Time Frame
preoperative, postoperative 1,7,30,90,180 days and one year
10. Eligibility
Sex
All
Minimum Age & Unit of Time
10 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patient with bullous keratopathy symptomatic (with pain)
Exclusion Criteria:
herpetic endotelial disorders
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Eliana D Gonçalves, MD
Organizational Affiliation
Federal University of São Paulo
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Automated Lamellar Keratectomy in Symptomatic Patients With Bullous Keratopathy
We'll reach out to this number within 24 hrs